InvestorsHub Logo
Followers 1
Posts 349
Boards Moderated 0
Alias Born 07/16/2014

Re: None

Wednesday, 04/27/2022 4:31:43 PM

Wednesday, April 27, 2022 4:31:43 PM

Post# of 18220
Statera Biopharma (Nasdaq: STAB) (the "Company"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company entered into a non-binding term sheet with respect to a strategic agreement with Immune Therapeutics, Inc. (OTC-PINK: IMUN), a drug development and commercialization company, to sell Statera's rights to naltrexone and met-enkephalin. The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.

"The agreement with Immune will enable us to strengthen our financial position with a transaction that has the potential to produce significant non-dilutive cashflow to fund our other programs. For instance, Statera is beginning to chart a new course in the immunotherapy field by pursuing molecules that act on Toll-like Receptor pathways similar to Naltrexone," said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma. "It also will help advance our new product candidates for treatment of a variety of immune-related diseases that have no cure."

Under the anticipated terms of the agreement, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Additionally, Statera will receive payments for achievement of revenue-based milestones, new indications and royalties, Crohn's disease and COVID-19 indications and regulatory approvals, as well as any other payments from Immune Therapeutics in exchange for Statera's rights to any product containing low-dose naltrexone as an active ingredient. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400 million in non-dilutive payments to Statera.

"Statera's naltrexone assets will be a great addition to our immune-modulation products and immunotherapy technologies," said Kevin Phelps, CEO, Immune Therapeutics. "We believe that they can significantly enhance our ability to combat chronic, life�threatening diseases and bring hope to millions of patients and their families."